Literature DB >> 10942425

Creation of a mouse model for non-neurological (type B) Niemann-Pick disease by stable, low level expression of lysosomal sphingomyelinase in the absence of secretory sphingomyelinase: relationship between brain intra-lysosomal enzyme activity and central nervous system function.

S Marathe1, S R Miranda, C Devlin, A Johns, G Kuriakose, K J Williams, E H Schuchman, I Tabas.   

Abstract

Most lysosomal storage diseases result in neurodegeneration, but deficiencies in the same enzymes can also lead to syndromes without neurologic manifestations. The hypothesis that low levels of residual, intra-lysosomal enzymatic activities in the central nervous system (CNS) are protective has been difficult to prove because of inconsistencies in assays of tissue samples. Experimental correction of lysosomal enzyme deficiencies in animal models suggests that low-level enzymatic activity may reduce CNS pathology, but these results are difficult to interpret owing to the partial and transient nature of the improvements, the presence of secretory hydrolases, and other confounding factors. Using a novel transgenic/knockout strategy to manipulate the intracellular targeting of a hydrolase, we created a mouse that stably expresses low levels of lysosomal sphingomyelinase (L-SMase) in the complete absence of secretory sphingomyelinase (S-SMase). The brains of these mice exhibited 11.5-18.2% of wild-type L-SMase activity, but the cerebellar Purkinje cell layer, which is lost by 4 months of age in mice completely lacking L- and S-SMase, was preserved for at least 8 months. The L-SMase activities in other organs were 1-14% of wild-type levels, and by 8 months of age all peripheral organs had accumulated sphingomyelin and demonstrated pathological intracellular inclusions. Most importantly, L-SMase-expressing mice showed no signs of the severe neurologic disease observed in completely deficient mice, and their life span and general health were essentially normal. These findings show that stable, continuous, low-level expression of intra-lysosomal enzyme activity in the brain can preserve CNS function in the absence of secretory enzyme or other confounding factors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942425     DOI: 10.1093/hmg/9.13.1967

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

Review 1.  An overview of sphingolipid metabolism: from synthesis to breakdown.

Authors:  Christopher R Gault; Lina M Obeid; Yusuf A Hannun
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  Widespread Expression of a Membrane-Tethered Version of the Soluble Lysosomal Enzyme Palmitoyl Protein Thioesterase-1.

Authors:  Charles Shyng; Shannon L Macauley; Joshua T Dearborn; Mark S Sands
Journal:  JIMD Rep       Date:  2017-02-18

3.  Cell-autonomous expression of the acid hydrolase galactocerebrosidase.

Authors:  Christina R Mikulka; Joshua T Dearborn; Bruno A Benitez; Amy Strickland; Lin Liu; Jeffrey Milbrandt; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2020-04-06       Impact factor: 11.205

4.  Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis.

Authors:  Anna Moles; Núria Tarrats; Albert Morales; Marlene Domínguez; Ramón Bataller; Juan Caballería; Carmen García-Ruiz; José C Fernández-Checa; Montserrat Marí
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

5.  Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span.

Authors:  Hee Kyung Jin; Janet E Carter; George W Huntley; Edward H Schuchman
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

Review 6.  Acid sphingomyelinase in macrophage biology.

Authors:  Jean-Philip Truman; Mohammed M Al Gadban; Kent J Smith; Samar M Hammad
Journal:  Cell Mol Life Sci       Date:  2011-05-02       Impact factor: 9.261

Review 7.  Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology.

Authors:  Catherine Pavoine; Françoise Pecker
Journal:  Cardiovasc Res       Date:  2009-01-28       Impact factor: 10.787

Review 8.  Gene Therapy for the Treatment of Neurological Disorders: Metabolic Disorders.

Authors:  Dominic J Gessler; Guangping Gao
Journal:  Methods Mol Biol       Date:  2016

Review 9.  Roles and regulation of secretory and lysosomal acid sphingomyelinase.

Authors:  Russell W Jenkins; Daniel Canals; Yusuf A Hannun
Journal:  Cell Signal       Date:  2009-06       Impact factor: 4.315

10.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.